Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

NCT04998669 is registered in ClinicalTrials.gov with Juan P. Alderuccio, MD as lead sponsor.

NCT NCT04998669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04998669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Lead sponsor
Juan P. Alderuccio, MD
Phase
Phase 2
Overall status
Recruiting
Start date
February 11, 2022
Completion date
August 1, 2030
Enrollment
100 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma